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The Burkholderia cepacia complex (Bcc) comprises at least 17 closely-related species of the β-proteobacteria subdivision, widely
distributed in natural and man-made inhabitats. Bcc bacteria are endowed with an extraordinary metabolic diversity and emerged
in the 1980s as life-threatening and diﬃcult-to-treat pathogens among patients suﬀering from cystic ﬁbrosis. More recently, these
bacteria became recognized as a threat to hospitalized patients suﬀering from other diseases, in particular oncological patients. In
the present paper, we review these and other traits of Bcc bacteria, as well as some of the strategies used to identify and validate
the virulence factors and determinants used by these bacteria. The identiﬁcation and characterization of these virulence factors is
expected to lead to the design of novel therapeutic strategies to ﬁght the infections caused by these emergent multidrug resistant
human pathogens.
1. The Burkholderia cepacia
Complex—An Overview
Members of the Burkholderia cepacia complex (Bcc) are
gram-negative bacteria of the β-proteobacteria subdivision
and include plant, animal, and human pathogens, with a
widespread distribution in natural and man-made inhabitats
[1]. These bacteria exhibit an extraordinary metabolic
versatility, allowing their adaptation to a wide range of
environments. Among the Bcc bacteria, several strains of
potentialenvironmentalapplicationhavebeenidentiﬁeddue
to their ability to degrade pollutants in water and soils (e.g.,
crude oils, herbicides, recalcitrant aromatic compounds, and
xenobiotics). A summary of Burkholderia strains capable
of degrading recalcitrant xenobiotics is available at the
Biodegradative Strain Database (http://bsd.cme.msu.edu/).
Several Bcc strains are also able to produce antifungal com-
pounds and to ﬁx atmospheric nitrogen [2]. Recent evidence
suggests that members of the Burkholderia genus are ancient
nitrogen-ﬁxing symbionts of Mimosa legumes particularly
adapted to acidic infertile soils [3]. Due to the ability of
some strains to promote plant growth, bacteria of the Bcc
have attracted signiﬁcant commercial interest as biocontrol,
bioremediation, and plant-growth promoting agents, mainly
due to their ability to colonize the rhizosphere of several
crops of economical interest, like corn, maize, rice, pea, and
sunﬂower [2]. However, these bacteria have also emerged as
important human pathogens and the risks associated with
the agricultural uses of Bcc strains remain unclear. There is
a general consensus that the large-scale use of organisms of
the Burkholderia g e n u si si m p r u d e n tu n t i lm o r ei sk n o w n
about the fate of biocontrol strains after their release in the
environment. The pathogenic mechanisms and traits used
by these bacteria, the clinical outcomes of infected patients,
and the interaction of the introduced biocontrol strains with
environmental and clinical strains need further studies [2].
Presently, there is some evidence that the environment can
be a reservoir for the acquisition of novel Bcc infections.
For example, the epidemic B. cenocepacia strain PHDC was
recovered both from patients suﬀering from cystic ﬁbrosis
(CF) in the mid-Atlantic region of USA, as well as from
agricultural soils [4].2 International Journal of Microbiology
2. Bcc asOpportunisticPathogens inHumans
In the last 30 years, several epidemiological, taxonomic,
and molecular biology studies of Bcc strains have been
carried out by research groups worldwide, mainly due to the
ability of these strains to cause chronic infections among CF
patients. CF is the most frequent hereditary disorder among
Caucasians. The disease results from mutations in the cystic
ﬁbrosis transmembrane conductance regulator (CFTR), a
cAMP-dependent chloride channel, mainly expressed in the
apical membrane of epithelial cells [5]. The genetic defect
resultsinmultipleorgansystemimpairment,beingtherespi-
ratorytractthemostaﬀected.Chronicpulmonaryinfections,
although caused by a limited number of bacterial species
(e.g., Pseudomonas aeruginosa,B c c ,Staphylococcus aureus,
Haemophilus inﬂuenza,a n dStenotrophomonas maltophilia),
remain the leading cause of death of these patients [5]. The
large majority of respiratory infections among CF patients
are due to P. aeruginosa strains [6]. Compared to this major
pathogen, Bcc strains infect a relatively small fraction of CF
patients. However, Bcc infections are particularly feared by
CF patients and their caregivers since the clinical outcome
is highly variable and unpredictable, ranging from asymp-
tomatic carriage to the cepacia syndrome [1]. Additionally,
in the vast majority of CF patients, pulmonary colonization
with Bcc is associated with a worst prognosis, including an
accelerated decline of the patients’ clinical status and an
increased risk of death [6].
Bcc bacteria are also important pathogens in other
compromised patients, as is the case of patients suﬀering
from chronic granulomatous disease (CGD) [7]. CGD is a
rare hereditary disease that is caused by mutations in the
subunits of the NADPH oxidase complex of the phagocytes,
resulting in their inability to produce reactive oxygen species
[7]. Invasive Bcc infections and pneumonia is the second
leading cause of death of CGD patients [7]. There are also
some reports of Bcc infections in immunocompromised
patients such as cancer and HIV patients, and also among
immunocompetent individuals [8, 9]. In immunocompetent
individuals, Bcc strains have been isolated in cases of
chronic suppurative otitis media, pharyngeal infections, and
paediatric neck infections [9]. In recent years, an increasing
number of bacteraemia cases caused by Bcc among non-
CF hospitalized patients have been reported. Most of these
patients have comorbidities such as chronic hemodialysis,
diabetes mellitus, congestive heart failure, and malignancy.
Among these hospitalized non-CF patients, hemodialysis,
permanence in intensive care units, use of central venous
catheters, indwelling urinary catheters, and endotracheal
tubes are now recognized as risk factors contributing for
Bcc acquisition. The accumulating reports of nosocomial
outbreaks caused by Bcc led to the recognition of these
bacteria as emergent nosocomial pathogens among non-CF
patients, in particular among oncology patients [8].
The Bcc comprises at least seventeen distinct species,
genetically distinct but phenotypically similar [10, 11]
(Table 1). Strains from all the Bcc species have been isolated
from CF patients and from the environment, however, their
frequency of isolation is uneven [12]. While the majority of
the isolates obtained from CF patients belong to the species
B. cenocepacia and B. multivorans [12], the majority of the
enviromental isolates belong to the species B. cepacia, B.
ambifaria, B. cenocepacia,a n dB. pyrrocinia [2].
A considerable phenotypic variability has been found
for all the Bcc species [13], even within sequential clinical
isolates of the same strain [20]. This phenotypic variability
diﬃcults the correct identiﬁcation of Bcc strains by diagnos-
tic microbiology laboratories [17]. Several phenotypic and
genetic methods have been used for the identiﬁcation of Bcc
species, including whole-cell protein proﬁle, fatty acid anal-
ysis, and 16S rRNA and recA gene restriction and sequencing
analysis [2]. However, the genetic methods have proven to
be the most eﬀective for the correct identiﬁcation of Bcc
strains. Nowadays, the multilocus sequence typing scheme
(MLST) is considered the golden standard method for the
identiﬁcation of Bcc species [21]. MLST analysis compares
the nucleotide sequence of seven house-keeping genes of Bcc
and the information obtained for each strain sequence type
(ST) is stored in a public database (http://pubmlst.org/bcc/),
thus allowing its use worlwide [21]. Recently, this method
was redesigned in a nested-PCR MLST format that can be
used for the accurate identiﬁcation of Bcc strains directly
from sputum samples [19]. This approach allowed the
identiﬁcation of Bcc strains in 23 sputum samples obtained
from 17 CF patients, of which 8 samples where culture was
negative [19]. In addition, the performance of MLST directly
with sputum samples also allowed the identiﬁcation of Bcc
strains from CF patients with mixed Bcc infections or co-
infected with P. aeruginosa strains, without the need for
strain isolation [19].
3.Burkholderia cepacia Complex Infections in
CysticFibrosis Patients
Bcc bacteria emerged as important CF pathogens during the
1980s, when some infected patients exhibited a rapid clinical
deterioration due to necrotizing pneumonia and sepsis,
resultinginearlydeath[22].Thisfataldeclineinthepatient’s
clinical condition became known as the cepacia syndrome
and was not observed for patients infected with any of the
other CF pathogens. The key determinants associated with
the cepacia syndrome are not completely understood, and
both bacterial and host factors are thought to play important
roles in determining this dramatic clinical outcome [23, 24].
Several strains of the species B. multivorans, B. cenocepacia,
B. cepacia,a n dB. dolosa have been shown to be highly
transmissible among CF patients through social contact
[25, 26]. In particular, highly epidemic lineages of the
B. cenocepacia species have been described, including the
Electrophoretic Type 12 (ET12), the Philadelphia-District
of Columbia (PHDC), and the MidWest epidemic lineages
[27, 28]. These epidemic strains can have an international
impact,asisthecaseofthehighlytransmissibleET12lineage.
This epidemic lineage spread among individuals with CF
from Canada, UK, and other European countries, being able
to replace B. multivorans and causing a high mortality due
to its ability to cause the cepacia syndrome [14, 23, 29].International Journal of Microbiology 3
Table 1: Burkholderia cepacia complex species and strains with their genome sequences ﬁnished or in progress. The Bcc genomes here
described are summarized in the Burkholderia genome database (http://www.burkholderia.com/viewAllGenomes.do).
Bcc Species Sources and Relevant
Characteristics Strains sequenced Unﬁnished genomes References
B. cepacia
Infections in Humans (CF and
non-CF); bioremediation and
biocontrol agent
[13]
B. multivorans Infections in Humans (CF and
non-CF) ATCC17616 CGD1, CGD2, CGD2M [13]
B. cenocepacia Infections in Humans (CF and
non-CF); biocontrol agent
J2315, AU1054, HI2424,
MCO-3, PC184 Bu72 [14]
B. stabilis Infections in Humans (CF and
non-CF)
[15]
B. vietnamiensis
Infections in Humans (CF and
non-CF); bioremediation and
biocontrol agent
G4 [13]
B. dolosa Infections in CF patients AU0158 [16]
B. ambifaria Infections in Humans (CF and
non-CF); biocontrol agent
AMMD, MC40-6, MEX-5,
IOP40-10
[17]
B. pyrrocinia Infections in CF patients;
biocontrol agent
[18]
B. anthina Infections in Humans (CF and
non-CF)
[18]
B. ubonensis Nosocomial infection Bu [10]
B. latens Infections in CF patients [10]
B. diﬀusa
Infections in Humans (CF and
non-CF), isolated from water and
soil
[10]
B. arboris Infections in Humans (CF and
non-CF), environmental sources
[10]
B. seminalis Infections in Humans (CF and
non-CF), environmental sources
[10]
B. metallica Infections in CF patients [10]
B. contaminans Infections in CF patients and in
animals
[11, 19]
B. lata Isolates from forest soil 383 [11]
Duetotheeasytransmissionofhighlyvirulentstrainsamong
CF patients, segregation measures of Bcc-infected patients
have been successfully implemented and led to the reduction
of the transmission of Bcc strains [30].
TheprevalenceofBccspeciesvariesgeographically,being
B. cenocepaciathe most predominant species in CF centers in
North America, while B. multivorans is the most common
s p e c i e si nE u r o p e a nC Fc e n t e r s[ 31]. However, outbreaks
caused by other Bcc species have occurred worldwide. For
instance, in the major Portuguese CF centre, B. cepacia is the
most prevalent Bcc species. In addition, an outbreak of B.
cepaciawasreportedandassociatedwiththeuseofnonsterile
saline solutions for nasal application [32]. Bcc outbreaks
among non-CF populations, mainly due to strains of the
species B. cenocepacia, B. cepacia, and B. multivorans are
also well documented [33]. Accumulating evidence points
out contaminated pharmaceuticals, cosmetics, disinfectants,
and preservative products as major sources of Bcc bacteria
[9, 34]. This is due to their ability to survive in these
products. In hospital settings, these pathogens have been
recovered from tap and distilled water, dialysis machines,
nebulisers, catheters, blood gas analysers, thermometers,
ventilator temperature sensors, solutions, and intravenous
ﬂuids [9].
One of the major problems associated with Bcc infection
is their intrinsic resistance to most of the clinically avail-
able antimicrobials, including aminoglycosides, quinolones,
polymyxins, and β-lactams [35]. The multiresistance of Bcc
bacteria appears to result from various eﬄux pumps that
eﬃcientlyremoveantibiotics fromthecell,decreased contact
ofantibioticswiththebacterialcellsurfaceduetotheirability
toformbioﬁlms,andchangesinthecellenvelopethatreduce
the permeability of the membrane to the antibiotic [36].
Bcc bacteria are also resistant to neutrophil-mediated non-
oxidative killing and to the antimicrobial peptides produced
byairwayepithelialcells,includinglysozyme,lactoferrin,and
phospholipase A2 [37]. Therefore, CF patients chronically
infected with Bcc are diﬃcult to treat and, although current4 International Journal of Microbiology
treatment strategies use double or triple antibiotic combi-
nations to achieve bactericidal activity, they rarely result in
the eradication of the pathogen, particularly in the case of
chronic infection [36].
4. Organization of Bcc Genomes
In 2003, the Wellcome Trust Sanger Institute sequenced the
ﬁrst genome of a Bcc strain. The strain chosen was the type
strain of the ET12 epidemic lineage, the B. cenocepacia strain
J2315 (http://www.sanger.ac.uk/Projects/B cenocepacia/).
Presently, the genomic sequences of 18 strains from 7Bcc
species are publicly available (http://pathema.jcvi.org/cgi-
bin/Burkholderia/PathemaHomePage.cgi). The genomes of
Bcc bacteria are organized in three circular chromosomal
replicons and one to ﬁve megaplasmids, ranging from 6.2
to 8.7Mbp in size, with a GC content of about 67%. The
large size and repartition of the genomes of Bcc is thought
to increase their ﬂexibility to acquire and lose genes. In a
recent bioinformatics study, Cooper et al. (2010) suggested
that the genes located in secondary chromosomes exhibit
a weaker codon usage bias than those located in primary
chromosomes, being subject to a faster evolutionary rate
[38]. Several evidences point out that more than 10%
of the Bcc genomes have been acquired by horizontal
gene transfer, contributing to the genomic plasticity and
metabolic diversity of these bacteria. For example, in the case
of the B. cenocepacia strain J2315, 14 genomic islands, most
probably arisen from horizontal gene transfer, have been
identiﬁedbasedontheirdistinctGCcontentpercentage[39].
The acquisition of genomic islands appears to play a crucial
role in the evolution of this particular epidemic lineage,
introducing new functions that promoted survival and
pathogenesis in the CF lung. This is the case of the 31.7kb
cci pathogenicity island, which appears to be unique to B.
cenocepacia strains [40]. This pathogenicity island encodes
both virulence and metabolism-associated genes, including
the CciIR quorum sensing system, a fatty acid biosynthesis
operon, transcriptional regulators, and genes involved in the
metabolism of amino acids [40]. In addition, the genome
of B. cenocepacia J2315 contains 79 insertion sequence
(IS) elements that are most probably involved in genomic
rearrangements, replicon fusion, activation/silencing of gene
expression, mobilization of DNA, and recruitment of foreign
genes [39]. Another feature of the genomes of Bcc bacteria is
thepresenceofmultiplepathwayswithrelatedfunctions,and
gene redundancy due to the occurrence of paralogous genes.
Sequencing of several Bcc genomes, followed by com-
parative genomics, is a powerful tool for the identiﬁcation
of virulence-associated genes of Bcc bacteria, including
new genes encoding proteins with no predicted function.
In the sequenced Bcc genomes, the percentage of protein
encoding genes with unknown function varies between 13
and 35% (http://img.jgi.doe.gov/cgi-bin/pub/main.cgi). It is
quite possible that a signiﬁcant percentage of these genes
of unknown function might be involved, either directly or
indirectly, in the pathogenesis of Bcc bacteria.
5. Strategies to Discover New Bcc Virulence
Factors and Determinants
Diﬀerent strategies have been designed to identify path-
ogenicity-related genes from Bcc bacteria, including the gen-
eration of mutant libraries with transposons and plasposons,
systematic gene-by-gene inactivation and high-throughput
sequencing, as illustrated in Figure 1. Our research group
has been using a strategy based on the generation of mutant
libraries from B. cenocepacia and B. cepacia strains by
random mutagenesis with plasposons [41], followed by
rescue of the interrupted genes, sequencing and comparison
of the nucleotide sequence of the interrupted genes with the
available genome sequences of Bcc strains, combined with
the virulence assessment in the Bcc infection models X-CGD
mice and/or Caenorhabditis elegans. A mutant library
derived from B. cepacia IST408 allowed the identiﬁcation
of the bce-I gene cluster that encodes proteins and enzymes
involved in the biosynthesis of the exopolysaccharide
(EPS) Cepacian [42]. Cepacian is composed of a branched
acetylated heptasaccharide repeat unit with D-glucose, D-
rhamnose, D-mannose, D-galactose, and D-glucuronic acid,
in the ratio 1:1:1:3:1, respectively [43]. Several studies
have shown that Cepacian interfered with the phagocytosis
of bacteria by human neutrophils and, inhibits neutrophil
chemotaxis, and the production of reactive oxygen species
[44, 45]. The ability to produce this EPS was also associated
with persistence of infection in the BALB/c and X-CGD
mice models of infection [44, 46]. Studies performed with
cepacian-defective mutants have also shown that cepacian is
requiredfortheformationofthickandmaturebioﬁlms[47].
Bioﬁlm formation in vitro is a common trait of Bcc strains
andhasbeenassociatedwiththepersistenceofBccinfections
[48]. In addition, bacteria of the Bcc growing in bioﬁlms
have been found to be more resistant to antimicrobials
than those growing plancktonically. It is also worth to
mention that in a recent study by Dales et al. (2009), bioﬁlms
formed by Bcc were found to be more resistant to antibiotics
compared to P. aeruginosa bioﬁlms [49]. Remarkably, a
mutant producing about one half of the amount of the
EPS was recently found to carry a plasposon insertion
interrupting a gene encoding the RNA chaperone Hfq [50].
Hfq proteins are global regulators of metabolism, acting as
RNA chaperones involved in the riboregulation of target
mRNAs by small regulatory noncoding RNAs (sRNAs),
facilitating the interaction with their target mRNAs [51].
The B. cepacia hfq mutant was shown to be more susceptible
to stress conditions, particularly to those that mimicked the
lung environment of the CF host, indicating that Hfq plays
a major role in the survival of Bcc bacteria under those stress
conditions[50].Inaddition,thehfqmutantsfromB.cepacia,
B. dolosa,a n dB. ambifaria exhibited a reduced ability to
colonize and kill the nematode C. elegans, indicating that
Hfq is an important virulence determinant of Bcc bacteria.
In agreement with the roles played by Hfq in other bacteria,
Sousaetal.(2010)havealsoshownthattheB.cepaciaIST408
Hfq is able to bind to sRNAs. Recently, 213 putative sRNAs
were identiﬁed within the genome of B. cenocepacia J2315,International Journal of Microbiology 5
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Figure 1: Strategies used to identify Bcc virulence factors and determinants.
based on the combination of comparative genomics and
prediction of their secondary structures [52]. Work in
progress envisages the identiﬁcation and characterization of
sRNAs from Bcc to gain clues on their possible contributions
to virulence.
Another mutant library, derived from the highly epi-
demic strain B. cenocepacia J2315, allowed the identiﬁcation
of a gene encoding an acyl carrier protein (ACP) [53].
Bacterial ACPs play a central role in metabolism, being the
donorsoftheacylmoietythatisrequiredforthebiosynthesis
of fatty acids, phospholipids, endotoxins, glycolipids, and
signallingmoleculesthatarenecessaryforgrowthandpatho-
genesis[54].Theacpmutantexhibitedanincreasedabilityto
form bioﬁlms in vitro, a more hydrophobic cell surface, and
reduced ability to colonize and kill the nematode C. elegans,
indicating that ACP protein is a virulence determinant for
B c cb a c t e r i a[ 53]. In addition, the amino acid sequence
and structural diﬀerences between the ACP proteins from
bacteria and humans make this protein an attractive target
for the development of novel antimicrobial compounds
[55].
Am u t a n tl i b r a r yf r o mB. cenocepacia K56-2 was also
constructed. The screen of this library for mutants impaired
in their ability to kill the nematode C. elegans allowed the
identiﬁcation of the regulatory protein Pbr. The pbr mutant
exhibited a pleiotropic phenotype, being unable to produce
phenazines, exhibited a reduced resistance to stresses such as
oxidative and osmotic stress, and a reduced ability to survive
prolonged nutrient starvation periods [56].
A signature-tagged mutagenesis (STM) strategy was used
byHuntetal.toidentifyputativevirulencefactorsofBcc[57]
(Figure 1). STM is a comparative hybridization technique
that uses a collection of transposons, each modiﬁed by the
incorporation of a DNA sequence tag [57]. The pool of
mutants is inoculated into a chronic pulmonary infection
animal model and the bacteria recovered after infection are
identiﬁed due to the tags. Mutants containing a transposon
insertion in genes required for survival will fail to pass
throughtheinvivoselection,thusallowingtheidentiﬁcation
of these genes. This strategy led to the identiﬁcation of
several B. cenocepacia K56-2 genes that were required for
bacterial survival in a rat model of chronic lung infection,
including genes involved in cellular metabolism, global
regulation, DNA replication and repair, cell surface proteins,
and polysaccharide production [57].
A suppression-subtractive hybridization (SSH) strategy
was used to identify genes that are unique to the B. cenocepa-
cia and/or to ET12 epidemic lineage strains [58]( Figure 1).
Recently, a high-throughput sequencing strategy was used
to compare the transcriptional response of clinical and
environmental strains of B. cenocepacia [59]( Figure 1). This
strategy revealed a large number of regulatory diﬀerences
between environmental and clinical strains, which might
result from speciﬁc adaptations to each of the diﬀerent
niches, despite their high degree of DNA sequence similarity.
Genes that encode for molecular chaperones and iron
acquisition proteins were found to be particularly induced
in the clinical strain [59].6 International Journal of Microbiology
All these strategies have allowed the identiﬁcation of
several genes putatively involved in the virulence of Bcc
strains. However, the characterization of knockout mutants
in these genes is hampered by limited available genetic
tools and the inherent resistance of Bcc strains to the
most common antibiotics used for genetic selection. In
this context, some research groups have been developing
molecular tools to genetically manipulate Bcc strains. For
instance, Lefebre and Valvano (2002) constructed several
expression vectors that contain the dhfr gene, encoding the
dihydrofolate reductase enzyme required for trimethoprim
resistance, together with either the constitutive promoter of
the S7 ribossomal protein gene from Burkholderia sp LB400,
or the arabinose-inducible BAD promoter from Escherichia
coli [60]. However, the concentration of arabinose required
for maximal gene expression [2% (w/v) or higher] causes
a change in cell volume typical of osmotic stress [61].
As a consequence, the full complementation of a given
mutation using these vectors is seldom achieved, limiting its
use [50]. Therefore, those authors have constructed another
expression vector, containing the rhamnose-regulated PrhaB
promoter of E. coli that allows maximal gene expression at
low concentrations of rhamnose [61]. Another limitation
derives from the fact that the B. cenocepacia J2315 strain is
a poor recipient of DNA in transformation and conjugation.
As an example, transformation of B. cepacia IST408 with
plasposon pTnMod was 104-fold more eﬃcient than B.
cenocepacia J2315 (S. A. Sousa and J. H. Leit˜ ao, unpublished
results). Recently, the electroporation procedure for this
strain was modiﬁed to increase its transformation eﬃciency
[62]. Factors that contribute to this improvement include
the addition of glycine to the growth medium to weaken
the thick cell wall, demethylation of transforming DNA by
extraction from a E. coli dam dcm host strain to escape to
the J2315 restriction system speciﬁc for methylated GATC
sites, the inclusion of the Ocr protein in the transformation
mixture to act as a decoy to inhibit Type I restriction
endonuclease attack of entering DNA, and the use of
spermine to reduce the resistance of the B. cenocepacia J2315
strain to several antibiotics [62]. Other strategies used to
eﬀectively generate Bcc mutants rely on the lambda red
recombinase system, as proposed by Datsenko and Wanner
(2000) [63]. This strategy uses linear DNA transformations
and has allowed the successful homologous expression of a
lipase gene in B. cepacia [64], as well the construction of an
insertion mutant in B. cenocepacia J2315 BCAL1538 (C. G.
Ramos, S. A. Sousa, J. H. Leit˜ ao, unpublished results).
A combination of one or more of the previous
approaches has allowed the identiﬁcation of several potential
virulence factors, including the cable pili and various
adhesins [65], ﬂagella [66], a type III and a type VI secretion
systems [67, 68], lipopolysaccharide [69], four types of iron-
chelating siderophores (salicylic acid, ornibactin, pyochelin,
cepaciachelin, and cepabactin) [70], production of extracel-
lular proteins, like proteases, lipases, and haemolysins [71,
72], quorum-sensing systems [73, 74], and others (recently
reviewed in [75]). However, not all strains produce each
of these virulence factors, and none of these factors has
been clearly demonstrated to be a major contributor to
human disease. In fact, contrasting with other pathogens,
the pathogenicity of Bcc bacteria does not rely on a single
gene. Accumulating evidences point out that Bcc virulence
is polygenic, involving genes related to survival under stress
conditions [50, 76–78]. Nevertheless, the Bcc genome is
equipped with the known crucial genes for colonization
and initiation of chronic infection in the respiratory tract,
which are involved in motility, adhesion, and host tissue
damage. Another important feature of some Bcc strains is
their ability to invade and survive inside eukaryotic cells,
including soil-dwelling amoebae, human macrophages, and
airway epithelial cells [79].
6. Concluding Remarks
Members of the Bcc have emerged in the last decades as
important pathogens to human, animals, and plants. The
pathogenicityofthesebacteriaispolygenic,andthusinvolves
a multitude of known and unknown virulence factors and
determinants. Several strategies have been successfully used
by several research groups to reveal novel and unknown
virulence factors and determinants. The knowledge of the
molecular mechanisms employed by Bcc bacteria for viru-
lence and pathogenesis is of crucial importance to identify
new targets for the rational design of novel strategies and/or
molecules to combat Bcc infections, since their resistance
to most of the clinically-relevant antimicrobials renders the
infections untreatable. In order to be regarded as a potential
drug target, a given gene or gene product must be essential
for survival of the pathogen in the host and should be
conserved in the various strains of the pathogen, while
presenting little or no conservation in humans. Genome-
based strategies, including genome sequencing, microarray-
based expression technology, and large-scale mutagenesis
studies, are expected to contribute, in the near future, for
the development of new strategies and/or antimicrobials
molecules to ﬁght the devastating and presently diﬃcult-to-
treat infections caused by Bcc strains.
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